Drug Development Collaboratory (UG3/UH3 Clinical Trial Required)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development Branch (TDB) and extramural researchers, for therapeutic development of small molecules, biologics, or gene therapies. The UG3 phase will provide support for late stage pre-clinical work and clinical trial planning that is conducted at applicant institutions. The goal of any collaboration with TDB is to enable an IND application by the end of the UG3 phase. If UG3 milestones are met and an IND is cleared, support may be provided for an early stage clinical trials in the UH3 phase that will be conducted at the applicant institutions.


  • Letter of Intent Due Date(s): 30 days prior to the application due date

  • AIDS Application Due Date(s): February 9, 2021; June 9, 2021; February 9, 2022; June 9, 2022; February 9, 2023; June 9, 2023

PAR-20-301 Expiration Date June 10, 2023




Medical - Translational

External Deadline

June 9, 2023